MX2020003832A - Compuestos heteroarilos como moduladores alostericos positivos del receptor muscarinico m1. - Google Patents

Compuestos heteroarilos como moduladores alostericos positivos del receptor muscarinico m1.

Info

Publication number
MX2020003832A
MX2020003832A MX2020003832A MX2020003832A MX2020003832A MX 2020003832 A MX2020003832 A MX 2020003832A MX 2020003832 A MX2020003832 A MX 2020003832A MX 2020003832 A MX2020003832 A MX 2020003832A MX 2020003832 A MX2020003832 A MX 2020003832A
Authority
MX
Mexico
Prior art keywords
muscarinic
positive allosteric
allosteric modulators
receptor positive
heteroaryl compounds
Prior art date
Application number
MX2020003832A
Other languages
English (en)
Inventor
Ramakrishna Nirogi
Anil Karbhari Shinde
Pradeep Jayarajan
Abdul Rasheed Mohammed
Vinod Kumar Goyal
Venkateswarlu Jasti
Srinivas Ravella
Vanaja Middekadi
Saivishal Daripelli
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MX2020003832A publication Critical patent/MX2020003832A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se relaciona con compuestos de formula (I), o sus formas isotopicas, estereoisomeros, tautomeros o sal o sales farmaceuticamente aceptables de los mismos como moduladores alostericos positivos del receptor M1 muscarinico (PAM M1); la presente invencion describe la preparacion, la composicion farmaceutica y el uso de la formula del compuesto (I).
MX2020003832A 2017-10-18 2018-10-17 Compuestos heteroarilos como moduladores alostericos positivos del receptor muscarinico m1. MX2020003832A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741037090 2017-10-18
PCT/IB2018/058047 WO2019077517A1 (en) 2017-10-18 2018-10-17 HETEROARYL COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF M1 MUSCARINIC RECEPTOR

Publications (1)

Publication Number Publication Date
MX2020003832A true MX2020003832A (es) 2020-08-06

Family

ID=64277732

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003832A MX2020003832A (es) 2017-10-18 2018-10-17 Compuestos heteroarilos como moduladores alostericos positivos del receptor muscarinico m1.

Country Status (16)

Country Link
US (1) US11234979B2 (es)
EP (1) EP3697790B1 (es)
JP (1) JP7104783B2 (es)
KR (1) KR102438588B1 (es)
CN (1) CN111212840B (es)
AU (1) AU2018353544B2 (es)
BR (1) BR112020007606A2 (es)
CA (1) CA3076757C (es)
EA (1) EA039781B1 (es)
IL (1) IL273748B (es)
MA (1) MA50402A (es)
MX (1) MX2020003832A (es)
NZ (1) NZ764004A (es)
SG (1) SG11202003284RA (es)
WO (1) WO2019077517A1 (es)
ZA (1) ZA202002034B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019082140A1 (en) * 2017-10-27 2019-05-02 Suven Life Sciences Limited POLYCYCLIC AMIDES AS POSITIVE ALLOSTERIC MODULATORS OF M1 MUSCARINIC RECEPTOR
EA202191046A1 (ru) * 2018-10-17 2021-07-12 Сувен Лайф Сайенсиз Лимитед Производные пирролопиридазина, как позитивные аллостерические модуляторы мускаринового рецептора m1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011062853A1 (en) 2009-11-20 2011-05-26 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide m1 receptor positive allosteric modulators
TW201512197A (zh) 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
MX2016001942A (es) 2013-09-27 2016-06-02 Hoffmann La Roche Derivados de indol e indazol.
GB201317363D0 (en) * 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
WO2016172547A1 (en) 2015-04-24 2016-10-27 Vanderbilt University Substituted imidazopyridine and triazolopyridine analogs as positive allosteric modulators of muscarinic acetylcholine receptor m1
ME03379B (me) 2015-06-08 2020-01-20 Suven Life Sciences Ltd Pozitivni alosterni modulatori muskarinskog m1 receptora
LT3347349T (lt) 2015-09-10 2019-12-10 Suven Life Sciences Ltd Fluorindolo dariniai kaip muskarininio m1 receptoriaus teigiami alosteriniai moduliatoriai

Also Published As

Publication number Publication date
EP3697790A1 (en) 2020-08-26
NZ764004A (en) 2023-03-31
EA039781B1 (ru) 2022-03-14
MA50402A (fr) 2021-05-19
CN111212840B (zh) 2022-07-22
SG11202003284RA (en) 2020-05-28
JP7104783B2 (ja) 2022-07-21
US11234979B2 (en) 2022-02-01
KR102438588B1 (ko) 2022-08-31
CA3076757A1 (en) 2019-04-25
EP3697790B1 (en) 2023-01-18
US20200237761A1 (en) 2020-07-30
AU2018353544A1 (en) 2020-04-16
EA202090925A1 (ru) 2020-07-13
JP2021500323A (ja) 2021-01-07
ZA202002034B (en) 2021-05-26
AU2018353544B2 (en) 2020-09-17
KR20200069330A (ko) 2020-06-16
CA3076757C (en) 2022-10-11
IL273748B (en) 2022-06-01
CN111212840A (zh) 2020-05-29
BR112020007606A2 (pt) 2020-09-29
WO2019077517A1 (en) 2019-04-25
IL273748A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
CY1123479T1 (el) Θετικοι αλλοστερικοι διαμορφωτες μουσκαρινικου υποδοχεα μ1
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
PE20151437A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
PE20151427A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
SV2016005351A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
UY35275A (es) Derivados de aminopirazina
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
ECSP17069696A (es) Compuestos novedosos
PH12017501280B1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
UY36003A (es) Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina.
CR20170484A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
CL2020001817A1 (es) Moduladores del receptor c5a
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
MX2020004339A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
MX2020003832A (es) Compuestos heteroarilos como moduladores alostericos positivos del receptor muscarinico m1.
CR20160373A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
ECSP18056196A (es) Derivados de indano
DOP2016000325A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
EA202191046A1 (ru) Производные пирролопиридазина, как позитивные аллостерические модуляторы мускаринового рецептора m1
BR112015026516A2 (pt) agentes antibacterianos de fenicol inovadores